However, it is important to consider the evidence base when interpreting the meaning of raised plasma biomarkers, recognizing that the primary source of the signal may be different in AD, where high levels of tau pathology are present, and DLB, where relatively low levels of tau pathology are present, particularly in early disease. This evidence concerns the gene MAPT and Lewy body dementia.